American Association for Cancer Research
Browse
mct-22-0414_supplementary_table_1_suppst1.docx (25.27 kB)

Supplementary Table 1 from A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes

Download (25.27 kB)
journal contribution
posted on 2023-04-03, 19:06 authored by Andres E. Perez Bay, Devon Faulkner, John O. DaSilva, Tara M. Young, Katie Yang, Jason T. Giurleo, Dangshe Ma, Frank J. Delfino, William C. Olson, Gavin Thurston, Christopher Daly, Julian Andreev

CRISPR RNA gene list

Funding

Regeneron Pharmaceuticals (Regeneron)

History

ARTICLE ABSTRACT

Most antibody–drug conjugates (ADC) approved for the treatment of cancer contain protease-cleavable linkers. ADCs that traffic to lysosomes traverse highly acidic late endosomes, while ADCs that recycle to the plasma membrane traffic through mildly acidic sorting and recycling endosomes. Although endosomes have been proposed to process cleavable ADCs, the precise identity of the relevant compartments and their relative contributions to ADC processing remain undefined. Here we show that a METxMET biparatopic antibody internalizes into sorting endosomes, rapidly traffics to recycling endosomes, and slowly reaches late endosomes. In agreement with the current model of ADC trafficking, late endosomes are the primary processing site of MET, EGFR, and prolactin receptor ADCs. Interestingly, recycling endosomes contribute up to 35% processing of the MET and EGFR ADCs in different cancer cells, mediated by cathepsin-L, which localizes to this compartment. Taken together, our findings provide insight into the relationship between transendosomal trafficking and ADC processing and suggest that receptors that traffic through recycling endosomes might be suitable targets for cleavable ADCs.

Usage metrics

    Molecular Cancer Therapeutics

    Categories

    Keywords

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC